Rare (often called “orphaned”) conditions don’t have population size for major pharmaceutical companies. But population size isn’t a concern for the individuals suffering from these conditions. Saol Therapeutics, a pharmaceutical company focused on rare neurological conditions engaged Epic Brand Group and Eletrope to launch a new treatment for severe spasticity related to cerebral palsy, stroke and traumatic brain injury. Eletrope defined the brand, designed informative digital properties for patients and healthcare providers, and supported conference attendance, both on the floor and in direct KOL presentations.